🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

Bayer sued for barring non-U.S. citizen from Roundup settlement

Published 01/19/2023, 02:36 PM
Updated 01/19/2023, 04:36 PM
© Reuters. FILE PHOTO: A bridge is decorated with the logo of a Bayer AG, a German pharmaceutical and chemical maker in Wuppertal, Germany August 9, 2019. REUTERS/Wolfgang Ratta/File Photo
BAYGN
-
MON
-
BAYRY
-

By Jonathan Stempel

(Reuters) -A new U.S. lawsuit on Thursday accused Germany's Bayer AG (ETR:BAYGN) of illegally excluding a Virginia farmworker from a settlement over claims its Roundup weedkiller causes cancer, because she is not a U.S. citizen.

The complaint said Elvira Reyes-Hernandez, who used Roundup while working on tree farms before being diagnosed with non-Hodgkin's lymphoma in 2019, expected to share in a $412.8 million settlement with an average $120,000 payout.

But she said her law firms, who she is also suing, dismissed her from the case because of her Mexican citizenship in July 2021, seven months after they countersigned papers authorizing a payout.

Now represented by Public Citizen, the advocacy group founded by Ralph Nader, the 47-year-old plaintiff said Bayer (OTC:BAYRY), its Monsanto (NYSE:MON) business and the law firms violated federal civil rights law by preventing her from recovering for her cancer, now in remission.

Reyes-Hernandez's lawsuit filed in federal court in Abingdon, Virginia seeks unspecified damages and a requirement that Bayer let non-U.S. citizens, who comprise more than 70% of agricultural crop farmworkers, join in Roundup settlements.

"Her citizenship status has nothing to do with her right to recover for harm from Bayer's products," said Kathryn Youker, a lawyer from the Lawyers' Committee for Civil Rights Under Law who helped file the lawsuit.

In a statement, Bayer said Reyes-Hernandez's lawsuit had no merit, and she was "no different" from other ineligible claimants.

"Bayer believes strongly in an inclusive, equitable and diverse culture and has no tolerance for racism or discrimination," it added.

After her claim was rejected, Reyes-Hernandez found a new lawyer, and in July sued Monsanto in St. Louis County, Missouri. Her former law firms did not respond to requests for comment.

Bayer's share price has fallen 44% since it paid $63 billion for Monsanto in June 2018, becoming the world's largest supplier of seeds and pesticides but also inheriting liability for Roundup litigation.

In June 2020, Bayer agreed to settle much of that litigation for $10.9 billion. As of February 2022, about 107,000 of the 138,000 claims it faced had been settled or deemed ineligible.

© Reuters. FILE PHOTO: A bridge is decorated with the logo of a Bayer AG, a German pharmaceutical and chemical maker in Wuppertal, Germany August 9, 2019. REUTERS/Wolfgang Ratta/File Photo

Last June, the U.S. Supreme Court let stand awards of $87 million and $25 million against Bayer to people who blamed their cancer on its weedkillers.

The case is Reyes-Hernandez v Monsanto Co et al, U.S. District Court, Western District of Virginia, No. 23-00001.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.